Stillbirth and fetal free haemoglobin
-
Authors list
Dr Ian Crocker, Dr Paul Brownbill, Professor Alexander Heazell, Anna Hoaksey
-
Research centre
Many babies that are stillborn show signs that there isn’t enough blood flow in the placenta. Sometimes, the blood vessels in the placenta can become too narrow, stopping the baby from getting the nutrients and oxygen it needs. If this goes on for too long, the baby might not be able to grow properly. In the worst cases, the baby’s blood supply can be completely cut off.
Researchers supported by Tommy’s have found that something called cell free fetal haemoglobin might be involved in restricting the blood supply in the placenta. Haemoglobin is a protein that exists in all of our red blood cells. It’s the substance that picks up oxygen so that our blood can transport it around the body. While the baby is growing in the womb, it makes a type of haemoglobin that is slightly different to an adult’s: it binds to oxygen more strongly. This helps the baby to get all the oxygen it needs from the mother’s blood.
If a baby’s haemoglobin is not contained in red blood cells – cell free fetal haemoglobin – it can remove substances in the blood that help the blood vessels to widen. Usually, free haemoglobin is taken out of the blood by an enzyme called HO-1. However, if there is not enough of this enzyme, free haemoglobin is left in the blood, causing the blood vessels to narrow. In turn, this will decrease the flow of blood in the placenta.
To understand better how this can increase the risk of stillbirth, Tommy’s are funding PhD student Anna Hoaksey, to carry on looking at the role of fetal haemoglobin. She will try to find out how levels of HO-1 can get low enough to be harmful, as well as studying potential ways of stopping the blood vessels from becoming too narrow.
In her recent work, Anna has confirmed that babies with weakened circulation do have the highest levels of cell free fetal haemoglobin. We have identified a drug called hydroxychloroquine (HCQ) that could be used to counteract this problem. Our experiments have shown that HCQ can stop fetal haemoglobin from making the blood vessels too narrow. As HCQ can safely cross the placenta, our next steps are to test this in clinical trials for the treatment of fetal growth restriction and stillbirth.
In the future, this vital work has the potential to find new drugs that will prevent stillbirth.
Get our research updates
Tommy's funds research across the UK investigating the reasons for pregnancy complications and loss. We can keep you updated on our research news. If you're interested in being kept updated about our research and news from Tommy's, click here.
This study is fully funded by Tommy's and takes place in a Tommy's centre
Read more on this topic
-
Research into stillbirth
When a baby dies after 24 weeks of gestation, it is called a stillbirth. Nearly 3000 families a year get the devastating news that their baby is not alive. Our research is helping to change this. -
The AFFIRM trial for prevention of stillbirth
Researchers supported by Tommy’s are looking at whether a package of care and resources for pregnant women can help stop stillbirths. -
Assessing how healthy babies are when they start moving less than normal (FEMINA2)
Reduced fetal movements are a common reason for women to go to hospital in the last 12 weeks of pregnancy. There is currently no way to know which women will have a normal pregnancy and which have problems. -
Assessing how healthy babies are when they start moving less than normal (FEMINA3)
Reduced fetal movements are a common reason for women to go to hospital in the last 12 weeks of pregnancy. But there is still no way to accurately tell which women will have a normal pregnancy, and which will have problems. -
Bile acid levels increases the risk of poor outcomes of pregnancies with intrahepatic cholestasis of pregnancy (ICP)
Researchers have looked at information from 5,500 women with ICP, finding that the babies of women with high bile acid levels are most at risk of stillbirth. -
Homing peptides: targeting drugs to the placenta
Drugs which could help prevent pregnancy complications can’t reach the placenta effectively. Tommy’s researchers are making use of ‘homing peptides’ to deliver drugs directly to the placenta. This work could help to prevent pregnancy complications and stillbirth. -
Can low levels of taurine make stillbirth more likely?
Tommy’s researchers are looking at how the lack of an important nutrient might harm the placenta during pregnancy, putting women at a higher risk of stillbirth. -
Can steroid injections improve blood flow to babies at risk of stillbirth?
Finding out whether steroids can improve the blood flow through the placenta -
Comparing 2D and 3D MRI to study the placenta
Our scientists are developing new ways to use MRI scans to study the placenta, so that we can understand how it works and how its structure and function change during pregnancy. This will help us prevent complications like stillbirth and miscarriage. -
Could beetroot juice be used to treat fetal growth restriction?
Fetal growth restriction is often caused by reduced blood flow across the placenta. Researchers funded by Tommy’s have found that beetroot juice, which is rich in a nutrient called nitrate, could potentially reduce blood pressure and improve blood flow to placenta. -
Improving support in a pregnancy after stillbirth or neonatal death (the IMPS study)
Our study aims to find out more about people's experiences of care in pregnancy after a loss and what extra support they would find helpful. -
Diabetes, fetal growth and stillbirth
Women suffering from type 1 or type 2 diabetes are more likely to suffer from stillbirths. We want to help people with diabetes to have healthy pregnancies.